EUCTR2013-005376-17-NL进行中（未招募）不适用
Sandostatin therapy in sarcoidosis - SST in SA
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age above 18 years with obtained written consent
- •Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years.
- •Have a positive SRS
- •Involvement of skin, joint, lymph nodes or lung. Patients with pulmonary involvement have a diffusing capacity between 60 and 75 percent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Corticosteroid use up to three months prior of trial
- •Chronic renal failure defined as a GFR below 50%
- •Liver disease
- •Have an indication for intensifying immunosuppressive therapy; threatening organ damage
- •Have received anti TNF-a therapy
- •Have an underlying cardiac disease
研究者
相似试验
已完成
2 期
Sandostatin therapy in sarcoidosisSarcoidosis10003816NL-OMON40194Erasmus MC, Universitair Medisch Centrum Rotterdam20
招募中
不适用
Sandostatin therapy in sarcoidosisSarcoidosis, sandostatinSarcoïdose, sandostatineNL-OMON25865Erasmus Medical Center, Department of Internal Medicine.20
进行中（未招募）
1 期
Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR.EUCTR2014-003856-30-BECliniques Universitaires Saint Luc50
已完成
2 期
Azithromycin a Treatment for Pulmonary SarcoidosisSarcoidosis, PulmonaryNCT04020380Hull University Teaching Hospitals NHS Trust21
已完成
3 期
Efficacy and Safety of Influenza Vaccine During SarcoidosisInfluenza VaccineSarcoidosisNCT01687517Assistance Publique - Hôpitaux de Paris190